Phathom Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 452
- Market Cap
- $1B
- Website
- http://www.phathompharma.com
- Introduction
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
A Study in Adult and Adolescent Participants With EoE to Evaluate Vonoprazan 10 mg and 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 10 mg and 20 mg Up to 52 Weeks
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06851559
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Vonoprazan ODT-1 or ODT-2 without WaterDrug: Vonoprazan ODT-1 or ODT-2 with WaterDrug: Vonoprazan (Reference)
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06831344
- Locations
- 🇺🇸
7551 Metro Center Dr Ste 200, Austin, Texas, United States
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
- Conditions
- Erosive EsophagitisHeartburnSymptomatic Non-erosive Gastroesophageal Reflux DiseaseHelicobacter Pylori Infection
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 728
- Registration Number
- NCT06660342
- Locations
- 🇺🇸
PPD, Wilmington, North Carolina, United States
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
- Conditions
- Erosive EsophagitisHeartburnSymptomatic Nonerosive Gasroesophageal Reflux DiseaseHelicobacter Pylori Infection
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06391177
- Locations
- 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06106022
- Locations
- 🇺🇸
Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States
🇺🇸Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States
🇺🇸Maspons Pediatric Gastro, El Paso, Texas, United States
A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05366738
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05343364
- Locations
- 🇺🇸
Infinite Clinical Trials, Morrow, Georgia, United States
🇺🇸Boston Specialists, Boston, Massachusetts, United States
🇺🇸University of South Alabama (USA) Physicians Group, Mobile, Alabama, United States
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
- Conditions
- Non-Erosive Gastro-Esophageal Reflux DiseaseHeartburn
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 776
- Registration Number
- NCT05195528
- Locations
- 🇺🇸
Paragon Rx Clinical, Garden Grove, California, United States
🇺🇸East View Medical Research, LLC, Mobile, Alabama, United States
🇺🇸Medical Affiliated Research Center Inc, Huntsville, Alabama, United States
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
- Conditions
- Non-Erosive Gastro-Esophageal Reflux DiseaseHeartburn
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 458
- Registration Number
- NCT04799158
- Locations
- 🇺🇸
North Alabama Research Center LLC, Athens, Alabama, United States
🇺🇸OM Research LLC, Lancaster, California, United States
🇺🇸Medication Management LLC, Greensboro, North Carolina, United States
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04729101
- Locations
- 🇺🇸
Celerion, 2420 W Baseline Rd,, Tempe, Arizona, United States